CTLA4 and cancer: This is consistent with the phenomenon of rheumatic immune-related adverse events, where the application of immune checkpoint therapy (anti-PD1/anti-CD152) in cancer results in rheumatic diseases.34 The presence of this inflammatory subset was further verified when we separately compared relapse against healthy non-JIA individuals.